FDA Grants Priority Review for Ultragenyx's DTX401 Gene Therapy BLA for GSDIa

summarizeSummary

Ultragenyx announced that the FDA accepted its BLA for DTX401 AAV gene therapy for GSDIa, granting it Priority Review with a PDUFA date of August 23, 2026.

check_boxKey Events

• FDA Accepts BLA for DTX401

  The FDA accepted Ultragenyx's Biologics License Application for DTX401 AAV gene therapy for Glycogen Storage Disease Type Ia (GSDIa).

• Priority Review Granted

  The BLA was granted Priority Review, indicating the FDA's expedited review process for drugs that offer significant improvements in the treatment, diagnosis, or prevention of serious conditions.

• PDUFA Date Set

  A Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026, has been assigned, providing a clear timeline for a potential regulatory decision.

auto_awesomeAnalysis

The FDA's acceptance of the Biologics License Application (BLA) for DTX401 with Priority Review is a significant positive development for Ultragenyx. This accelerates the review process for a potential new gene therapy for Glycogen Storage Disease Type Ia (GSDIa), a rare genetic disorder. The assigned PDUFA date of August 23, 2026, provides a clear timeline for a regulatory decision. This news offers a strong positive counterpoint to recent setbacks, including the failure of the UX143 study and an Incomplete Response Letter for UX111, demonstrating continued pipeline progress and diversification.